{
    "eid": "2-s2.0-84944182869",
    "title": "Drug use evaluation of Letrozole in breast cancer patients at regional cancer hospitals in Thailand",
    "cover-date": "2015-01-01",
    "subject-areas": [
        {
            "$": "Public Health",
            "@code": "2739"
        },
        {
            "$": "Oncology",
            "@code": "2730"
        },
        {
            "$": "Cancer Research",
            "@code": "1306"
        },
        {
            "$": "Epidemiology",
            "@code": "2713"
        }
    ],
    "keywords": [
        "Breast cancer",
        "Drug use evaluation",
        "Letrozole",
        "Rational drug use"
    ],
    "authors": [
        "Chaninun Ketkaew"
    ],
    "citedby-count": 3,
    "ref-count": 29,
    "ref-list": [
        "Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy",
        "Hormone-responsive breast cancer",
        "Letrozole: A well-tolerated and effective treatment for breast cancer",
        "Approval summary: Letrozole (Femara\u00ae Tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: Conversion of accelerated to full approval",
        "Off-label use of oxaliplatin in patients with metastatic breast cancer",
        "Prescribing extended adjuvant letrozole",
        "Letrozole in the extended adjuvant setting: MA.17",
        "Kathmandu University, J Sci Eng Technol",
        "Training Course",
        "Srinagarin Med J",
        "Off-label use of anticancer drugs in eastern Switzerland: A population-based prospective cohort study",
        "Drug use evaluation of tamoxifen focusing on off-label use in a managed care population in Israel",
        "Letrozole: A review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer",
        "Off-label use of cancer drugs: A benchmark is established",
        "Letrozole: Advancing hormone therapy in breast cancer",
        "Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience",
        "Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen",
        "Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer",
        "Thai national formulary: special access medicines of national list of essential medicines",
        "National list of essential medicines Thailand 2009",
        "Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: A retrospective analysis",
        "Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8\u00b71 years median follow-up",
        "Letrozole: In postmenopausal hormone-responsive early-stage breast cancer",
        "Letrozole in the treatment of breast cancer",
        "Am J Pharmtech Res",
        "Reflections about off-label use of anticancer drugs",
        "Off-label and off-NCCN guidelines uses of antineoplastic drugs in China",
        "Promoting rational use of medicine: core component",
        "Results of letrozole in postmenopausal women after tamoxifen treatment for advanced breast cancer"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "affilname": "Chulalongkorn University",
        "affiliation-country": "Thailand"
    },
    "funding": []
}